SK142596A3 - Purin-6-one derivatives, process for producing them, pharmaceutical composition containing them and their use - Google Patents

Purin-6-one derivatives, process for producing them, pharmaceutical composition containing them and their use Download PDF

Info

Publication number
SK142596A3
SK142596A3 SK1425-96A SK142596A SK142596A3 SK 142596 A3 SK142596 A3 SK 142596A3 SK 142596 A SK142596 A SK 142596A SK 142596 A3 SK142596 A3 SK 142596A3
Authority
SK
Slovakia
Prior art keywords
group
carbon atoms
straight
branched
branched alkyl
Prior art date
Application number
SK1425-96A
Other languages
English (en)
Slovak (sk)
Inventor
Ulrich Niewoehner
Erwin Bischoff
Joachim Huetter
Elisabeth Perzborn
Helmuth Schuetz
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of SK142596A3 publication Critical patent/SK142596A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SK1425-96A 1995-11-06 1996-11-05 Purin-6-one derivatives, process for producing them, pharmaceutical composition containing them and their use SK142596A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19541264A DE19541264A1 (de) 1995-11-06 1995-11-06 Purin-6-on-derivate

Publications (1)

Publication Number Publication Date
SK142596A3 true SK142596A3 (en) 1997-05-07

Family

ID=7776713

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1425-96A SK142596A3 (en) 1995-11-06 1996-11-05 Purin-6-one derivatives, process for producing them, pharmaceutical composition containing them and their use

Country Status (23)

Country Link
US (1) US5861396A (es)
EP (1) EP0771799A1 (es)
JP (1) JPH09124648A (es)
KR (1) KR970027082A (es)
AR (1) AR004545A1 (es)
AU (1) AU720305B2 (es)
BR (1) BR9605434A (es)
CA (1) CA2189401A1 (es)
CO (1) CO4770977A1 (es)
CZ (1) CZ325096A3 (es)
DE (1) DE19541264A1 (es)
EE (1) EE9600172A (es)
HU (1) HU217691B (es)
IL (1) IL119559A0 (es)
MX (1) MX9605371A (es)
NO (1) NO964667L (es)
NZ (1) NZ299683A (es)
PL (1) PL316816A1 (es)
SG (1) SG64953A1 (es)
SK (1) SK142596A3 (es)
TR (1) TR199600883A2 (es)
TW (1) TW360656B (es)
ZA (1) ZA969278B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69815554T2 (de) * 1998-01-05 2004-05-06 Eisai Co., Ltd. Purinderivate und antagonisten des adenosin-a2-rezeptors, welche zur vorsorge oder heilung von diabetes dienen
DE19838705A1 (de) 1998-08-26 2000-03-02 Bayer Ag Neue Dihydro-(1,2,3)-triazolo-[4,5-d]pyrimidin-7-one
GB9828340D0 (en) * 1998-12-22 1999-02-17 Novartis Ag Organic compounds
US20050020547A1 (en) * 1999-11-08 2005-01-27 Pfizer Inc. Compounds for the treatment of female sexual dysfunction
IL139457A0 (en) * 1999-11-08 2001-11-25 Pfizer Compounds for the treatment of female sexual dysfunction
ES2233685T3 (es) * 2000-08-01 2005-06-16 Bayer Healthcare Ag Inhibidores selectivos de pde 2 como medicamentos para mejorar la percepcion.
US20020065286A1 (en) * 2000-08-21 2002-05-30 Davies Michael John Treatment of wounds
AU2001284444B2 (en) * 2000-09-06 2006-05-25 Mitsubishi Tanabe Pharma Corporation Preparations for oral administration
DE10064105A1 (de) 2000-12-21 2002-06-27 Bayer Ag Neue Substituierte Imidazotriazinone
DE60236850D1 (de) * 2001-02-15 2010-08-12 Mitsubishi Tanabe Pharma Corp Tabletten, die in der mundhöhle schnell zerfallen
CZ20032258A3 (cs) 2001-02-23 2004-01-14 Merck & Co., Inc. N-substituované nearylové heterocyklické sloučeniny
US6479493B1 (en) 2001-08-23 2002-11-12 Cell Pathways, Inc. Methods for treatment of type I diabetes
PL370599A1 (en) * 2001-11-02 2005-05-30 Pfizer Products Inc. Treatment of insulin resistance syndrome and type 2 diabetes with pde9 inhibitors
CA2517336A1 (en) * 2003-03-04 2004-10-21 Altana Pharma Ag Purin-6-one-derivatives
US20040220186A1 (en) * 2003-04-30 2004-11-04 Pfizer Inc. PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
GB0314054D0 (en) * 2003-06-17 2003-07-23 Pfizer Ltd Amide derivatives as selective serotonin re-uptake inhibitors
US20050054688A1 (en) * 2003-08-08 2005-03-10 Pfizer Inc Selective serotonin reuptake inhibitors in the treatment of disease
AU2004268387A1 (en) * 2003-08-28 2005-03-10 Nycomed Gmbh Composition comprising a pulmonary surfactant and a PDE2 inhibitor
US7291640B2 (en) * 2003-09-22 2007-11-06 Pfizer Inc. Substituted triazole derivatives as oxytocin antagonists
GB0409744D0 (en) * 2004-04-30 2004-06-09 Pfizer Ltd Novel compounds
WO2006100588A1 (en) * 2005-03-21 2006-09-28 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
ES2313626T3 (es) * 2005-03-21 2009-03-01 Pfizer Limited Derivados de triazol sustituidos como antagonistas de oxitocina.
US20100222365A1 (en) * 2005-08-10 2010-09-02 Pfizer Inc Substituted triazole deriviatives as oxytocin antagonists
JP6696904B2 (ja) 2014-01-08 2020-05-20 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 製剤および医薬組成物
RU2702732C1 (ru) 2014-12-06 2019-10-10 Интра-Селлулар Терапиз, Инк. Органические соединения
BR112017012007B1 (pt) 2014-12-06 2022-11-01 Intra-Cellular Therapies, Inc Compostos orgânicos inibitórios de pde2, composições farmacêuticas compreendendo os ditos compostos e uso dos mesmos no tratamento de um distúrbio mediado por pde2

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4451478A (en) * 1982-03-12 1984-05-29 Newport Pharmaceuticals International, Inc. Imidazole compounds
IL76546A (en) * 1984-10-12 1988-12-30 Warner Lambert Co 9-(heteroarylalkyl)-6-purine(thi)one derivatives,their preparation and pharmaceutical compositions containing them
EP0290630A4 (de) * 1986-11-25 1990-02-26 Inst Organicheskogo Sinteza Ak 9-substituierte guanine.
IT1241452B (it) * 1990-06-28 1994-01-17 Sigma Tau Ind Farmaceuti Derivati oligopeptidici dell'ipoxantina dotati di attivita' immunomodulante e composizioni farmaceutiche che li contengono

Also Published As

Publication number Publication date
HU217691B (hu) 2000-03-28
ZA969278B (en) 1997-06-02
CZ325096A3 (en) 1997-06-11
AR004545A1 (es) 1998-12-16
CO4770977A1 (es) 1999-04-30
JPH09124648A (ja) 1997-05-13
HUP9603071A3 (en) 1998-04-28
US5861396A (en) 1999-01-19
CA2189401A1 (en) 1997-05-07
TR199600883A2 (tr) 1997-05-21
DE19541264A1 (de) 1997-05-07
EP0771799A1 (de) 1997-05-07
TW360656B (en) 1999-06-11
BR9605434A (pt) 1998-08-04
NZ299683A (en) 1998-09-24
AU720305B2 (en) 2000-05-25
NO964667D0 (no) 1996-11-05
AU7053296A (en) 1997-05-15
HUP9603071A2 (en) 1997-05-28
EE9600172A (et) 1997-06-16
KR970027082A (ko) 1997-06-24
NO964667L (no) 1997-05-07
SG64953A1 (en) 1999-05-25
MX9605371A (es) 1997-05-31
IL119559A0 (en) 1997-02-18
HU9603071D0 (en) 1996-12-30
PL316816A1 (en) 1997-05-12

Similar Documents

Publication Publication Date Title
SK142596A3 (en) Purin-6-one derivatives, process for producing them, pharmaceutical composition containing them and their use
JP3418405B2 (ja) カルボリン誘導体
CA2485872C (en) Derivatives of 2-(1-benzyl-1h-pyrazolo(3,4-b)pyridine-3-yl)-5-(4-pyridinyl)-4-pyrimidinamines and the use thereof as guanylate cyclase stimulators
US20090012103A1 (en) Substituted heterocyclic compounds
SK5912003A3 (en) Novel pyridine-substituted pyrazolopyridine derivatives
WO2012054332A1 (en) Substituted hydroxamic acids and uses thereof
SK287748B6 (sk) Substituované 5-amino-pyrazolo[4,3-e]-1,2,4-triazolo[1,5- c]pyrimidíny, spôsob ich výroby, farmaceutický prostriedok s ich obsahom a ich použitie
US7781453B2 (en) Aminopyridine-derivatives
IE66040B1 (en) Pyrazologpyrimidinone antianginal agents
JP2005501034A (ja) モルホリン架橋のピラゾロピリジン誘導体
JP2002529467A (ja) 勃起不全治療に効果を持つピラゾロピリミジノン化合物
JPH08231545A (ja) ２，９−ジ置換プリン−６−オン類
US20020169203A1 (en) Ion channel modulating agents
EP2383262A1 (en) Phenyl pyrimidone compounds, pharmaceutical compositions, preparation methods and uses thereof
PL164592B1 (pl) Sposób wytwarzania nowych pochodnych chromanu i tiochromanu PL PL PL PL PL PL PL
CZ16896A3 (en) 9-substituted 2-(2-n-alkoxyphenyl) purin-6-ones, process of their preparation, pharmaceutical composition such compounds and their use
PL173738B1 (pl) Sposób wytwarzania pochodnych pirolo(2,3-d)pirymidyny
RU2162470C2 (ru) 2,7-замещенные производные октагидропирроло[1,2-а]пиразина, способ лечения, фармацевтическая композиция, промежуточные соединения
JP3181305B2 (ja) 選択的アデノシン受容体アゴニスト及びアンタゴニスト
EP1023291B1 (en) Dipyridoimidazolderivatives useful in treating central nervous system disorders
Kuroda et al. Design, synthesis and biological evaluation of a novel series of potent, orally active adenosine A1 receptor antagonists with high blood-brain barrier permeability
JP2002322162A (ja) チアゾリジン誘導体
EP1973907B1 (en) Imidazo (1,2-a)pyridin-3-yl-acetic acid hydrazides, processes for their preparation and pharmaceutical uses thereof
WO2004022554A1 (en) Quinazolinone derivatives
WO2003035066A1 (en) 2-aminoquinolone derivatives for use as impdh inhibitors